Key result
DOACs show no significant difference vs. warfarin for recurrent cerebral venous thrombosis.
Why the study?
Warfarin is the cornerstone oral anticoagulant for cerebral venous sinus thrombosis (CVST), and although several RCTs suggest direct oral anticoagulants (DOACs) provide similar benefit, evidence comparing their efficacy and safety remains limited.
Do direct oral anticoagulants (DOACs) provide comparable efficacy in preventing recurrent venous thrombosis compared to warfarin in adults with cerebral venous sinus thrombosis?
Meta-Analysis (n=530)
Do direct oral anticoagulants (DOACs) provide comparable efficacy in preventing recurrent venous thrombosis compared to warfarin in adults with cerebral venous sinus thrombosis?
This meta-analysis of RCTs demonstrates that DOACs have comparable efficacy and safety to warfarin for cerebral venous sinus thrombosis, supporting their use as a practical alternative without routine monitoring.
Answers are grounded in this paper and cite their sources.
Recurrent CVT risk similar with DOACs versus warfarin; leaves open definitive equivalence given wide CI in this RCT meta-analysis.
Background: Cerebral Venous Sinus Thrombosis (CVST) is typically managed with parenteral heparin, followed by transition to oral anticoagulation (OAC) for long-term treatment. Although warfarin remains the cornerstone OAC therapy for CVST, recent studies and meta-analyses have demonstrated that Direct Oral Anticoagulants (DOACs) provide similar benefit. Despite the completion of several RCTs, evidence remains limited because the condition affects a particular subset of the population. Objective: To determine the efficacy and safety of Direct Oral Anticoagulants in the management of CVST as compared to warfarin. Methods: We searched PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov since their inception for Randomized Controlled Trials (RCTs) evaluating DOACs versus warfarin in adults with CVST. The primary efficacy outcome was recurrent venous thrombosis. Other outcomes included major hemorrhage and lack of recanalization. Results: A total of 530 patients were included, comprising 281 treated with DOACs and 249 with warfarin. The mean age of participants was 32.1 ± 12.3 years, with a female predominance (62.5%). The pooled analysis demonstrated no statistically significant difference between DOACs and warfarin in the risk of recurrent CVT (RR: 1.45; 95% CI: 0.37-5.63; p = 0.59; I² = 19.9%). Similarly, there was no significant difference in the risk of major hemorrhage (RR: 0.65; 95% CI:0.22-1.96; p = 0.45; I² = 0%) or failure of recanalization (RR: 1.10; 95% CI: 0.72-1.69; p =0.64; I² = 6.11%). Overall, these findings suggest that DOACs offer comparable safety and efficacy profiles to warfarin for the treatment of cerebral venous sinus thrombosis, with minimal heterogeneity across studies. Conclusion: DOACs demonstrated comparable risk of recurrent thrombosis, hemorrhagic complications, and failure of recanalization. DOACs offer a safe and practical alternative to warfarin, especially for CVST patients at risk of non-compliance with warfarin due to the lack of need for routine monitoring. There remains a need for well-powered studies to better define optimal anticoagulation strategies in this population.
No takes yet. Share an insight, caveat, or question.
Asmar et al. (2026) conducted a meta-analysis in Cerebral Venous Sinus Thrombosis (CVST) (n=530). Direct Oral Anticoagulants (DOACs) vs. Warfarin was evaluated on Recurrent venous thrombosis (recurrent CVT) (RR 1.45, 95% CI 0.37-5.63, p=0.59). DOACs showed no significant difference compared to warfarin in recurrent cerebral venous thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: